Literature DB >> 4038581

Lowered prealbumin levels in patients with familial amyloid polyneuropathy (FAP) and their non-affected but at risk relatives.

M Skinner, L H Connors, A Rubinow, C Libbey, J D Sipe, A S Cohen.   

Abstract

Amyloid fibrils in familial amyloid polyneuropathy, the familial (AF) form of systemic amyloidosis, are composed of the monomeric unit (14,000 MW) of prealbumin molecules. By radioimmunoassay, the serum level of prealbumin was measured in 25 patients from 12 different kinships with this dominantly inherited form of amyloidosis and 56 unaffected, but at risk, relatives from two of the kinships. Results were compared to prealbumin levels in normal individuals and patients with primary (AL) and secondary (AA) forms of systemic amyloidosis. Significantly lowered prealbumin levels were found in the AF patients (149.2 micrograms/ml) and their at risk relatives (169.0 micrograms/ml) when compared to normal individuals (232.9 micrograms/ml), AL patients (221.9 micrograms/ml) and AA patients (211.7 micrograms/ml). No abnormality was found in levels of retinol binding protein (RBP), which is carried by prealbumin, in the serum of either the AF patients or their relatives. The depressed prealbumin levels may indicate a structural variant molecular form, an extra hepatic synthesis or an abnormality in catabolism of this protein that is present prior to the clinical or histopathologic onset of the AF disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038581     DOI: 10.1097/00000441-198501000-00003

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  8 in total

1.  Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.

Authors:  Elena S Klimtchuk; Tatiana Prokaeva; Nicholas M Frame; Hassan A Abdullahi; Brian Spencer; Surendra Dasari; Haili Cui; John L Berk; Paul J Kurtin; Lawreen H Connors; Olga Gursky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

2.  Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.

Authors:  Jacquelyn L S Hanson; Marios Arvanitis; Clarissa M Koch; John L Berk; Frederick L Ruberg; Tatiana Prokaeva; Lawreen H Connors
Journal:  Circ Heart Fail       Date:  2018-02       Impact factor: 8.790

3.  A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction.

Authors:  Xin Jiang; Richard Labaudinière; Joel N Buxbaum; Cecília Monteiro; Marta Novais; Teresa Coelho; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

4.  Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity.

Authors:  Joel Buxbaum; James Koziol; Lawreen H Connors
Journal:  Amyloid       Date:  2008-12       Impact factor: 7.141

5.  Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin.

Authors:  Genki Suenaga; Tokunori Ikeda; Teruaki Masuda; Hiroaki Motokawa; Taro Yamashita; Kotaro Takamatsu; Yohei Misumi; Mitsuharu Ueda; Hirotaka Matsui; Satoru Senju; Yukio Ando
Journal:  Sci Rep       Date:  2017-05-08       Impact factor: 4.379

6.  First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers.

Authors:  Jonathan C Fox; Jennifer L Hellawell; Satish Rao; Terry O'Reilly; Rick Lumpkin; Jesper Jernelius; Daniel Gretler; Uma Sinha
Journal:  Clin Pharmacol Drug Dev       Date:  2019-06-06

Review 7.  The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism.

Authors:  Chiara Sanguinetti; Marianna Minniti; Vanessa Susini; Laura Caponi; Giorgia Panichella; Vincenzo Castiglione; Alberto Aimo; Michele Emdin; Giuseppe Vergaro; Maria Franzini
Journal:  Biomedicines       Date:  2022-08-06

Review 8.  Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist.

Authors:  Federico Perfetto; Mattia Zampieri; Carlo Fumagalli; Marco Allinovi; Francesco Cappelli
Journal:  Intern Emerg Med       Date:  2022-03-24       Impact factor: 5.472

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.